Navigation Links
Antibodies for new rotavirus vaccines
Date:7/17/2012

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

Rotavirus kills nearly half a million children every year, 85 per cent of whom live in developing countries. The virus is one of the most common causes of hospital and emergency admissions for children under five in Australia.

Since the introduction of two rotavirus vaccines, Rotarix and RotaTeq, to Australia's National Immunisation Program in 2007, hospitalisations of children under five years of age due to rotavirus gastroenteritis have been reduced by over 70 per cent.

PATH, an international not-for-profit organisation, is working to increase access to and effectiveness of existing commercial rotavirus vaccines worldwide, while also working with emerging-country vaccine manufacturers to speed up the development of safe, effective, and more affordable new rotavirus vaccines.

"CSIRO will produce a large quantity of antibodies specific to the strains of rotavirus that are in the vaccines our partners are developing, which will serve as important material for our project," said Dr Georges Thiry, director of PATH's rotavirus vaccine development project.

"New vaccines and suppliers will increase the availability of rotavirus vaccines and increase competition, which in turn will help make all of the rotavirus vaccines on the market more affordable and accessible to the world's most vulnerable children."

Dr George Lovrecz, group leader for CSIRO's protein production and fermentation group, is confident that CSIRO's expertise from the tissue culture and purification teams will deliver excellent results.

"We are proud to be assisting this groundbreaking project that is working to help save the lives of children in the world's poorest countries," he said.

CSIRO will use their recombinant protein production facility in Clayton, Victoria, for the large-scale production of the antibodies.

"This unique, state-of-the-art facility will allow us to produce enough antibodies to supply PATH's partners for the next five years," said Dr Lovrecz.

"We will be producing six antibodies that will be used to test the quality of the rotavirus vaccines being developed."

The antibodies, originally prepared by Dr Carl Kirkwood from the Murdoch Childrens Research Institute, will be used by PATH's manufacturing partners in China, Brazil, and India and by the United States' National Institutes of Health.


'/>"/>

Contact: Merrin Fabre
Merrin.Fabre@csiro.au
61-395-458-362
CSIRO Australia
Source:Eurekalert

Related medicine news :

1. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
2. Antibodies from rabbits reduce risks associated with
3. Antibodies reverse type 1 diabetes in new immunotherapy study
4. ACP Immunization Advisor app makes it easier for doctors to identify vaccines for patients
5. Control gene for conveyor belt cells could help improve oral vaccines, treat intestinal disease
6. OHSU Oregon National Primate Research Center develops new, safer method for making vaccines
7. World Health Assembly endorses new plan to increase global access to vaccines
8. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology: